Tags

Type your tag names separated by a space and hit enter

Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women.
Maturitas. 2019 Mar; 121:76-82.M

Abstract

A lack of estrogen due to menopause changes metabolic homeostasis, which increases the risk of metabolic syndrome (MetS) in postmenopausal women. Hormone therapy (HT) has beneficial effects on chronic diseases as well as on menopause symptoms. The aim of this study was to investigate the association of HT use with MetS and its components by diabetes status in middle-aged postmenopausal Korean women. A cross-sectional analysis was undertaken of a total of 39,295 non-diabetic and 3,359 diabetic postmenopausal women aged 40 to 69 years from the Health Examinees-Gem (HEXA-G) study (2004-2013). The mean differences in the MetS components by HT use were assessed using a general linear model and Tukey's multiple comparisons tests. The prevalence odds ratio (POR) and 95% confidence intervals (CIs) were estimated using the logistic regression model. HT use was associated with lower fasting glucose level, total cholesterol, systolic blood pressure, body mass index, waist circumference, and waist-to-hip ratio among both diabetic and non-diabetic women. In non-diabetic women, HT 'ever' use was negatively associated with the prevalence of MetS (POR = 0.80, 95% CI: 0.75-0.85), and current users had a lower prevalence of MetS (POR = 0.68, 95% CI: 0.60-0.76). A longer duration of HT use was associated with a decreasing prevalence of MetS. We did not find heterogeneity by age regarding MetS prevalence. Our results suggest that HT use is negatively associated with the prevalence of MetS among postmenopausal women. However, further longitudinal studies are required to investigate the effect of HT on MetS in Korean women.

Authors+Show Affiliations

Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.JW Lee Center for Global Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea; Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea; Institute of Environmental Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. Electronic address: jiyeob.choi@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30704569

Citation

Kim, Ji-Eun, et al. "Associations of Postmenopausal Hormone Therapy With Metabolic Syndrome Among Diabetic and Non-diabetic Women." Maturitas, vol. 121, 2019, pp. 76-82.
Kim JE, Choi J, Park J, et al. Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women. Maturitas. 2019;121:76-82.
Kim, J. E., Choi, J., Park, J., Lee, J. K., Shin, A., Park, S. M., Kang, D., & Choi, J. Y. (2019). Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women. Maturitas, 121, 76-82. https://doi.org/10.1016/j.maturitas.2018.12.012
Kim JE, et al. Associations of Postmenopausal Hormone Therapy With Metabolic Syndrome Among Diabetic and Non-diabetic Women. Maturitas. 2019;121:76-82. PubMed PMID: 30704569.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women. AU - Kim,Ji-Eun, AU - Choi,Jaesung, AU - Park,JooYong, AU - Lee,Jong-Koo, AU - Shin,Aesun, AU - Park,Sang Min, AU - Kang,Daehee, AU - Choi,Ji-Yeob, Y1 - 2018/12/20/ PY - 2018/09/07/received PY - 2018/12/10/revised PY - 2018/12/19/accepted PY - 2019/2/2/entrez PY - 2019/2/2/pubmed PY - 2019/3/23/medline KW - Diabetes KW - Hormone therapy KW - Menopause KW - Metabolic syndrome SP - 76 EP - 82 JF - Maturitas JO - Maturitas VL - 121 N2 - A lack of estrogen due to menopause changes metabolic homeostasis, which increases the risk of metabolic syndrome (MetS) in postmenopausal women. Hormone therapy (HT) has beneficial effects on chronic diseases as well as on menopause symptoms. The aim of this study was to investigate the association of HT use with MetS and its components by diabetes status in middle-aged postmenopausal Korean women. A cross-sectional analysis was undertaken of a total of 39,295 non-diabetic and 3,359 diabetic postmenopausal women aged 40 to 69 years from the Health Examinees-Gem (HEXA-G) study (2004-2013). The mean differences in the MetS components by HT use were assessed using a general linear model and Tukey's multiple comparisons tests. The prevalence odds ratio (POR) and 95% confidence intervals (CIs) were estimated using the logistic regression model. HT use was associated with lower fasting glucose level, total cholesterol, systolic blood pressure, body mass index, waist circumference, and waist-to-hip ratio among both diabetic and non-diabetic women. In non-diabetic women, HT 'ever' use was negatively associated with the prevalence of MetS (POR = 0.80, 95% CI: 0.75-0.85), and current users had a lower prevalence of MetS (POR = 0.68, 95% CI: 0.60-0.76). A longer duration of HT use was associated with a decreasing prevalence of MetS. We did not find heterogeneity by age regarding MetS prevalence. Our results suggest that HT use is negatively associated with the prevalence of MetS among postmenopausal women. However, further longitudinal studies are required to investigate the effect of HT on MetS in Korean women. SN - 1873-4111 UR - https://www.unboundmedicine.com/medline/citation/30704569/Associations_of_postmenopausal_hormone_therapy_with_metabolic_syndrome_among_diabetic_and_non_diabetic_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5122(18)30592-9 DB - PRIME DP - Unbound Medicine ER -